Last reviewed · How we verify
Remicade
At a glance
| Generic name | Remicade |
|---|---|
| Also known as | infliximab, Infliximab, Infliximab (European Union), Infliximab (United States), SCH 215596 |
| Sponsor | Shanghai Biomabs Pharmaceutical Co., Ltd. |
| Target | Tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Behcet's disease
- Crohn's disease
- Erythrodermic psoriasis
- Plaque psoriasis
- Psoriasis with arthropathy
- Pustular psoriasis
- Rheumatoid arthritis
- Ulcerative colitis
Common side effects
- Infections (upper respiratory, sinusitis, pharyngitis)
- Infusion-related reactions
- Headache
- Abdominal pain
- Fever or chills
- Cardiopulmonary reactions (chest pain, hypotension, hypertension, dyspnea)
- Pruritus
- Urticaria
- Dyspnea
- Flushing
- Rash
Serious adverse events
- Serious infusion reactions
- Anaphylaxis
- Convulsions
- Erythematous rash
- Hypotension
- Serious infusion reactions on re-administration
Key clinical trials
- Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease (NA)
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remicade CI brief — competitive landscape report
- Remicade updates RSS · CI watch RSS
- Shanghai Biomabs Pharmaceutical Co., Ltd. portfolio CI